Plain-English translation of NCT05834244 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination approach using , , and donated immune cells (called ) to treat acute myeloid leukemia, a serious blood cancer. The study is designed for older adults or people with other health conditions who cannot tolerate standard intensive chemotherapy. Researchers want to find the safest and most effective dose of this three-part treatment and see how well it works.
Acute myeloid leukemia is very difficult to treat, especially in older patients or those too frail for intensive chemotherapy. Current treatment options are limited and often don't work well enough. This trial explores whether combining these three treatments together might help more patients achieve remission and live longer.
You likely qualify if…
You likely don't qualify if…
You will receive the treatment in cycles, with the study having two phases: a dose-escalation phase to find the safest dose, and a dose-expansion phase to test that dose in more patients. You will receive and , along with infusions of donor . Throughout the trial, you'll have regular blood tests and bone marrow evaluations to monitor how your leukemia responds and to check for side effects. The study will track how long you stay in remission, your overall survival, and how your blood counts recover.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States